apo-fingolimod capsule
apotex inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents
mar-fingolimod capsule
marcan pharmaceuticals inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents
sandoz fingolimod capsule
sandoz canada incorporated - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents
ach-fingolimod capsule
accord healthcare inc - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents
jamp fingolimod capsule
jamp pharma corporation - fingolimod (fingolimod hydrochloride) - capsule - 0.5mg - fingolimod (fingolimod hydrochloride) 0.5mg - immunomodulatory agents
gilenya capsule 0.5mg
novartis (singapore) pte ltd - fingolimod hcl 0.56 mg eqv fingolimod - capsule - 0.5mg - fingolimod hcl 0.56 mg eqv fingolimod 0.5mg
gilenya
novartis europharm limited - fingolimod hydrochloride - multiple sclerosis - immunosuppressants - gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).orpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
gilenya capsule 0.25mg
novartis (singapore) pte ltd - fingolimod hcl 0.28mg eqv fingolimod - capsule - fingolimod hcl 0.28mg eqv fingolimod 0.25mg
fingolimod accord
accord healthcare s.l.u. - fingolimod hydrochloride - multiple sclerosis, relapsing-remitting - immunosuppressants, selective immunosuppressants - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapyorpatients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod genthon 0.5 mg, hard capsules
genthon bv microweg 22, 6545 cm nijmegen, netherlands - fingolimod - hard capsule - fingolimod 0.5 mg - immunosuppressants